Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Randomized Controlled Trial
. 2022 Jan 17;14(2):397.
doi: 10.3390/nu14020397.

Predictors of Symptom-Specific Treatment Response to Dietary Interventions in Irritable Bowel Syndrome

Affiliations
Randomized Controlled Trial

Predictors of Symptom-Specific Treatment Response to Dietary Interventions in Irritable Bowel Syndrome

Esther Colomier et al. Nutrients. .

Abstract

(1) Background: Predictors of dietary treatment response in irritable bowel syndrome (IBS) remain understudied. We aimed to investigate predictors of symptom improvement during the low FODMAP and the traditional IBS diet for four weeks. (2) Methods: Baseline measures included faecal Dysbiosis Index, food diaries with daily energy and FODMAP intake, non-gastrointestinal (GI) somatic symptoms, GI-specific anxiety, and psychological distress. Outcomes were bloating, constipation, diarrhea, and pain symptom scores treated as continuous variables in linear mixed models. (3) Results: We included 33 and 34 patients on the low FODMAP and traditional IBS diet, respectively. Less severe dysbiosis and higher energy intake predicted better pain response to both diets. Less severe dysbiosis also predicted better constipation response to both diets. More severe psychological distress predicted worse bloating response to both diets. For the different outcomes, several differential predictors were identified, indicating that baseline factors could predict better improvement in one treatment arm, but worse improvement in the other treatment arm. (4) Conclusions: Psychological, nutritional, and microbial factors predict symptom improvement when following the low FODMAP and traditional IBS diet. Findings may help individualize dietary treatment in IBS.

Keywords: NICE guidelines; diet; disorders of the gut brain interaction; dysbiosis; functional gastrointestinal disorders; gastrointestinal symptoms; irritable bowel syndrome; low FODMAP diet; prediction; treatment response.

PubMed Disclaimer

Conflict of interest statement

S.S. has served as advisory board member for Takeda and speaker for Viatris. H.T. has served as advisory board member/consultant for Almirall and Shire. L.V.O. is assistant research professor of the K.U. Leuven Special Research Fund (Bijzonder Onderzoeksfonds, BOF). J.T. has given scientific advice to Adare, AlfaWassermann, Allergan, Arena, Bayer, Christian Hansen, Clasado, Danone, Devintec, Falk, Grünenthal, Ironwood, Janssen, Kiowa Kirin, Menarini, Mylan, Neurogastrx, Neutec, Novartis, Noventure, Nutricia, Shionogi, Shire, Takeda, Theravance, Tramedico, Truvion, Tsumura, Zealand, and Zeria Pharmaceutical; received research support from Shire, Sofar, and Tsumura; and served on the Speakers Bureau for Abbott, Allergan, AstraZeneca, Janssen, Kyowa Kirin, Menarini, Mylan, Novartis, Shire, Takeda, Truvion, and Zeria Pharmaceutical, all outside the submitted work. L.Ö. has received a financial support for research by Genetic Analysis AS, Biocodex, Danone Research and AstraZeneca and served as a consultant/advisory board member for Genetic Analysis AS, and as a speaker for Biocodex, Ferring Pharmaceuticals, Takeda, AbbVie, and Meda. M.S. has received grants and personal fees from Glycom and Danone Nutricia Research; personal fees from Ironwood, Menarini, Biocodex, Adnovate, Arena, Tillotts, Kyowa Kirin, Takeda, Alimentary Health, AlfaSigma, and the Falk Foundation; and grants from Genetic Analysis AS, outside the submitted work. The remaining authors disclose no conflicts. The funders had no role in the design of the study; in the collection, analyses, or interpretation of data; in the writing of the manuscript, or in the decision to publish the results. The authors declare no conflict of interest.

Figures

Figure 1
Figure 1
Flow chart indicating the number of patients included in each study phase, for details see text. Fermentable oligo-, di-, monosaccharides, and polyols, FODMAP; Patient Health Questionnaire-12, PHQ-12; Visceral Sensitivity Index, VSI; Gastrointestinal Symptom Rating Scale-Irritable Bowel Syndrome, GSRS-IBS.
Figure 2
Figure 2
Predictors of pain improvement during the low FODMAP and traditional IBS diet. (a) Higher energy intake predicted better response to both diets. (b) Lower Dysbiosis Index scores predicted better response to both diets. (c) Oligosaccharide intake was a differential predictor with a non-significant association between higher baseline oligosaccharide intake and a worse response in low FODMAP treatment arm and (d) a significant association between higher baseline oligosaccharide intake and a better response in traditional IBS treatment arm. The GSRS-IBS subscales used in the linear mixed (i.e., random-effect) models were BoxCox transformed. For the transformation of the pain subscale, the following BoxCox formula was used: y(λ)=yλ1λ. This led to changes in the original score range score of 1–7 to 0–6, using the formula: y(1)=y111.
Figure 3
Figure 3
Predictors of constipation improvement during the low FODMAP and traditional IBS diet. (a) A lower Dysbiosis Index score predicted better response to both diets. (b) Disaccharide intake was a differential predictor with a non-significant association between higher baseline disaccharide intake and a worse response in low FODMAP treatment arm and (c) a significant association between higher baseline disaccharide intake and a better response in traditional IBS treatment arm. The GSRS-IBS subscales used in the linear mixed (i.e., random-effect) models were BoxCox transformed. For the transformation of the constipation subscale, the following BoxCox formula was used: y(λ)=yλ1λ. This led to changes in the original score range score of 1–7 to 0–3.29, using the formula: y(0.5)=y0.510.5.
Figure 4
Figure 4
Predictors of bloating improvement during the low FODMAP and traditional IBS diet. (a) Higher psychological distress predicted worse response to both diets. (b) Oligosaccharide intake was a differential predictor with a significant association between higher baseline oligosaccharide intake and a worse response in low FODMAP treatment arm and (c) a non-significant association between higher baseline oligosaccharide intake and a better response in traditional IBS treatment arm. The GSRS-IBS subscales used in the linear mixed (i.e., random-effect) models were BoxCox transformed. For the transformation of the bloating subscale, the following BoxCox formula was used: y(λ)=yλ1λ. This led to changes in the original score range score of 1–7 to 0–6, using the formula: y(1)=y111.

References

    1. Sperber A.D., Bangdiwala S.I., Drossman D.A., Ghoshal U.C., Simren M., Tack J., Whitehead W.E., Dumitrascu D.L., Fang X., Fukudo S., et al. Worldwide Prevalence and Burden of Functional Gastrointestinal Disorders, Results of Rome Foundation Global Study. Gastroenterology. 2021;160:99–114.e113. doi: 10.1053/j.gastro.2020.04.014. - DOI - PubMed
    1. Drossman D.A. Functional Gastrointestinal Disorders: History, Pathophysiology, Clinical Features and Rome IV. Gastroenterology. 2016;4:1257–1492. doi: 10.1053/j.gastro.2016.03.035. - DOI - PubMed
    1. Chang L., Lee O.Y., Naliboff B., Schmulson M., Mayer E.A. Sensation of bloating and visible abdominal distension in patients with irritable bowel syndrome. Am. J. Gastroenterol. 2001;96:3341–3347. doi: 10.1111/j.1572-0241.2001.05336.x. - DOI - PubMed
    1. Simrén M., Törnblom H., Palsson O.S., van Tilburg M.A.L., Van Oudenhove L., Tack J., Whitehead W.E. Visceral hypersensitivity is associated with GI symptom severity in functional GI disorders: Consistent findings from five different patient cohorts. Gut. 2018;67:255–262. doi: 10.1136/gutjnl-2016-312361. - DOI - PubMed
    1. Törnblom H., Van Oudenhove L., Sadik R., Abrahamsson H., Tack J., Simrén M. Colonic transit time and IBS symptoms: What’s the link? Am. J. Gastroenterol. 2012;107:754–760. doi: 10.1038/ajg.2012.5. - DOI - PubMed

Publication types

MeSH terms

Substances

LinkOut - more resources